Inhibrx Inc (INBX)
35.15
+0.08
(+0.23%)
USD |
NASDAQ |
Mar 27, 16:00
35.18
+0.04
(+0.10%)
Pre-Market: 20:00
Inhibrx Free Cash Flow: -197.90M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
December 31, 2023 | -197.90M |
September 30, 2023 | -168.51M |
June 30, 2023 | -144.27M |
March 31, 2023 | -128.90M |
December 31, 2022 | -115.99M |
September 30, 2022 | -108.01M |
June 30, 2022 | -91.03M |
March 31, 2022 | -86.58M |
December 31, 2021 | -81.19M |
September 30, 2021 | -74.30M |
Date | Value |
---|---|
June 30, 2021 | -74.64M |
March 31, 2021 | -63.52M |
December 31, 2020 | -49.33M |
September 30, 2020 | -45.61M |
June 30, 2020 | -32.91M |
March 31, 2020 | -35.71M |
December 31, 2019 | -33.89M |
September 30, 2019 | -35.13M |
June 30, 2019 | -35.84M |
Free Cash Flow Range, Past 5 Years
-197.90M
Minimum
Dec 2023
-32.91M
Maximum
Jun 2020
-84.38M
Average
-74.64M
Median
Jun 2021
Free Cash Flow Benchmarks
Johnson & Johnson | 17.78B |
Gilead Sciences Inc | 7.421B |
Outlook Therapeutics Inc | -47.10M |
Axonics Inc | -5.566M |
NovaBay Pharmaceuticals Inc | -5.043M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -56.82M |
Cash from Investing (Quarterly) | -3.442M |
Cash from Financing (Quarterly) | 0.86M |
Free Cash Flow Per Share (Quarterly) | -1.114 |
Free Cash Flow to Equity (Quarterly) | -61.51M |
Free Cash Flow to Firm (Quarterly) | -56.74M |
Free Cash Flow Yield | -11.95% |